These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25291308)

  • 21. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uncharted territories of the patent-restoration due-diligence challenge.
    Gaudry KS
    Food Drug Law J; 2011; 66(1):121-38, iii. PubMed ID: 24505850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favourable changes to the IP and tax systems in the UK for drug development.
    Watson R
    Expert Opin Ther Pat; 2013 Jul; 23(7):773-5. PubMed ID: 23713616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 25. Navigating the Safe Harbor: guidance from the courts on qualifying for the 35 U.S.C. 271(e)(1) exemption from patent infringement of health care related inventions.
    Chickos SJ
    J Contemp Health Law Policy; 2007; 24(1):43-68. PubMed ID: 18507356
    [No Abstract]   [Full Text] [Related]  

  • 26. Inter Partes Review: Patent Killer No More?
    Chen FC; Lee PS
    Trends Biotechnol; 2019 Jul; 37(7):680-683. PubMed ID: 30890272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Patent expiry for profitable drugs].
    López Tricas JM
    Farm Hosp; 2012; 36(1):1-2. PubMed ID: 22035601
    [No Abstract]   [Full Text] [Related]  

  • 28. India's rejection of Novartis's patent is but a small step in the right direction.
    Bhaumik S
    BMJ; 2013 Apr; 346():f2412. PubMed ID: 23596223
    [No Abstract]   [Full Text] [Related]  

  • 29. Pregabalin: what the patent litigation means for doctors and drug companies.
    Smyth D; Croker R; Goldacre B
    BMJ; 2018 Jun; 361():k2318. PubMed ID: 29880536
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV drug trademark case handed down in UK.
    Gold J
    Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):58-9. PubMed ID: 15108661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 33. Court upholds infringement of research tool patents, but discounts damages.
    Maebius SB; Warburg RJ
    Pharmacogenomics; 2003 Jul; 4(4):369-70. PubMed ID: 12831314
    [No Abstract]   [Full Text] [Related]  

  • 34. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are the UK courts clamping down on 'evergreening' strategies for the extension of patent protection?
    Albutt J
    Pharm Pat Anal; 2015 Jan; 4(1):1-3. PubMed ID: 25565154
    [No Abstract]   [Full Text] [Related]  

  • 36. Patent protection for medical technologies: why some and not others?
    Melzer D
    Lancet; 1998 Feb; 351(9101):518-9. PubMed ID: 9482467
    [No Abstract]   [Full Text] [Related]  

  • 37. Patent owner options for correcting errors in US patents after grant.
    Armstrong M
    Pharm Pat Anal; 2014 Sep; 3(5):499-508. PubMed ID: 25374319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panel rules against Canada on patent terms for pre-TRIPS patents.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):43, 45. PubMed ID: 11833196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 40. Patent watch: Progress in three key patent disputes in 2009.
    Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.